Comparing 5% Dextrose Injections Into or Around Partial Supraspinatus Tendon Tears
Intralesional Versus Perilesional 5% Dextrose Injection for Partial Supraspinatus Tendon Tears: A Randomized Controlled Trial
This prospective, single-center randomized trial compared ultrasound-guided intralesional and perilesional 5% dextrose injections in adults with partial supraspinatus tendon tears. Participants and outcome assessors were blinded to group assignment. Forty-six participants were randomized equally to the two groups, and 40 completed follow-up and were included in the final analysis (20 per group).
Both groups received ultrasound-guided injections at baseline and at study weeks 3 and 6. At each session, both groups received a 5% dextrose injection at the supraspinatus tendon attachment. An additional injection was given either directly into the tear or into the tendon tissue around it, depending on group assignment. Both groups began the same home exercise program after the first injection.
Shoulder pain, disability, and health-related quality of life were assessed at baseline and at study weeks 9 and 12. Tear dimensions and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.
研究概览
地位
详细说明
This prospective, single-center, parallel-group randomized trial enrolled adults aged 18 to 75 years with symptomatic partial supraspinatus tendon tears. An independent researcher generated the 1:1 allocation sequence using a computer-based random number generator. Allocation was concealed in sequentially numbered, opaque, sealed envelopes. The injecting physician opened the envelopes after the baseline clinical and ultrasonographic assessments. Participants and outcome assessors were blinded to group assignment.
Both groups received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, 2 mL was distributed across three points at the supraspinatus tendon enthesis in both groups. An additional 2 mL was injected into the tendon defect in the intralesional group or into the tendon tissue surrounding the defect in the perilesional group using a peppering technique. The total injection volume was 4 mL per session in both groups. Participants began the same standardized home exercise program after the first injection and were instructed to perform it twice daily throughout the study.
Clinical outcomes were assessed at baseline and at study weeks 9 and 12. Mean daytime pain, worst daytime pain, and night pain were recorded separately using the Numeric Rating Scale. Shoulder pain and disability were assessed using the Shoulder Pain and Disability Index, and health-related quality of life was assessed using the 12-Item Short Form Health Survey. Short-axis and long-axis defect diameters and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Ankara、土耳其(türkiye)
- Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18 to 75 years
- Shoulder pain and functional limitation for at least 3 months
- Partial supraspinatus tendon tear identified on magnetic resonance imaging performed within the previous 6 months and confirmed by ultrasonography at study entry. Articular-sided, bursal-sided, and intrasubstance tears were eligible.
- At least one positive Neer, Hawkins-Kennedy, or painful arc test
- Ability to attend follow-up visits
- Written informed consent to participate
For participants with bilateral involvement, only the more painful shoulder was included.
Exclusion Criteria:
- - Full-thickness supraspinatus tendon tear
- Major pathology of rotator cuff tendons other than the supraspinatus
- Advanced acromioclavicular or glenohumeral osteoarthritis
- Marked adhesive capsulitis
- Previous shoulder surgery
- Corticosteroid, platelet-rich plasma, or prolotherapy injection into the affected shoulder within the previous 3 months
- Active infection, including infection at the injection site
- Skin lesion at the injection site
- Bleeding diathesis or anticoagulant use
- Known allergy or intolerance to dextrose
- Uncontrolled diabetes mellitus (HbA1c >8.5%)
- Severe endocrine or metabolic disease
- Immunosuppression
- Rheumatologic disease involving the shoulder
- Neurological disease affecting shoulder function
- Pregnancy
- Active malignancy
- Cognitive impairment preventing reliable completion of questionnaires
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intralesional 5% Dextrose Injection
Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and directly into the partial tendon tear. Participants began the same standardized home exercise program as the perilesional group after the first injection. |
At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected directly into the partial tendon defect using a peppering technique. The total volume was 4 mL per session. |
|
有源比较器:Perilesional 5% Dextrose Injection
Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and into the tendon tissue surrounding the margins of the partial tear. Participants began the same standardized home exercise program as the intralesional group after the first injection. |
At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected into the tendon tissue surrounding the margins of the partial tear using a peppering technique. The total volume was 4 mL per session. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Shoulder Pain Intensity Assessed by Numeric Rating Scale
大体时间:Baseline and study weeks 9 and 12.
|
Mean daytime shoulder pain, worst daytime shoulder pain, and night pain were assessed separately using an 11-point Numeric Rating Scale (NRS). Each score ranged from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicated greater pain intensity. |
Baseline and study weeks 9 and 12.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability Index
大体时间:Baseline and study weeks 9 and 12.
|
The Shoulder Pain and Disability Index (SPADI) was used to assess shoulder pain and disability. The pain subscale contains 5 items, and the disability subscale contains 8 items. The two subscales were scored separately on a 0-100 scale. Higher scores indicated greater pain or disability. |
Baseline and study weeks 9 and 12.
|
|
Change in Health-Related Quality of Life Assessed by the Short Form-12 Health Survey
大体时间:Baseline and study weeks 9 and 12.
|
Health-related quality of life was assessed using the 12-Item Short Form Health Survey (SF-12). The Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated separately. Higher scores indicated better health-related quality of life in the corresponding component. |
Baseline and study weeks 9 and 12.
|
|
Change in Supraspinatus Tendon Thickness Assessed by Ultrasonography
大体时间:Baseline and study week 12.
|
Supraspinatus tendon thickness was measured in millimeters using shoulder ultrasonography with a 5-12 MHz linear transducer. |
Baseline and study week 12.
|
|
Change in Partial Rotator Cuff Defect Size Assessed by Ultrasonography
大体时间:Baseline and study week 12.
|
The short-axis and long-axis diameters of the partial supraspinatus tendon tear were measured separately in millimeters using electronic calipers on the ultrasound images that best displayed the defect. |
Baseline and study week 12.
|
合作者和调查者
调查人员
- 首席研究员:ESRA Ülgen Kıratlıoğlu、Ankara City Hospital Bilkent
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- E2-26-14590
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data will not be shared due to privacy and ethical restrictions.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.